key: cord-0829435-kjqb4yyk
authors: Kohli, Utkarsh; Desai, Lavina; Chowdhury, Devyani; Harahsheh, Ashraf S.; Yonts, Alexandra B.; Ansong, Annete; Sabati, Arash; Nguyen, Hoang H.; Hussain, Tarique; Khan, Danyal; Parra, David A.; Su, Jennifer A.; Patel, Jyoti K.; Ronai, Christina; Bohun, Monique; Freij, Bishara J.; O’Connor, Matthew J.; Rosanno, Joseph W.; Gupta, Aamisha; Salavitabar, Arash; Dorfman, Adam L.; Hansen, Jesse; Frosch, Olivia; Profita, Elizabeth L.; Maskatia, Shiraz; Thacker, Deepika; Shrivastava, Shubhika; Harris, Tyler; Feingold, Brian; Berger, Stuart; Campbell, Michael; Idriss, Salim F.; Das, Srikant; Renno, Markus S.; Knecht, Ken; Asaki, S. Yukiko; Patel, Sunil; Ashwath, Ravi; Shih, Renata; Phillips, John; Das, Bibhuti; Ramachandran, Preeti; Sagiv, Eyal; Bhat, Aarti H.; Johnson, Jonathan N.; Taggart, Nathaniel; Imundo, Jason; Nakra, Natasha; Behere, Shashank; Patel, Anjlee; Agarwal, Avichal; Aljemmali, Saif; Lang, Sean; Batlivala, Sarosh; Forsha, Daniel E.; Conners, Gregory P.; Shaw, Jana; Smith, Frank C.; Pauliks, Linda; Vettukattil, Joseph; Shaffer, Kenneth; Cheang, Stefanie; Voleti, Sonia; Shenoy, Rajesh; Komarlu, Rukmini; Ryan, Shea J.; Snyder, Christopher; Bansal, Neha; Sharma, Madhu; Robinson, Jeffrey; Arnold, Sandra R.; Salvatore, Christine M.; Kumar, Madan; Fremed, Michael; Glickstein, Julie S.; Perrotta, Melissa; Orr, William; Rozema, Tamika; Thirumoorthi, Muthayipalayam; Mullett, Charles J.; Ang, Jocelyn Y.
title: mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study
date: 2021-12-22
journal: J Pediatr
DOI: 10.1016/j.jpeds.2021.12.025
sha: 34bb7867f20e7258297e64062b93e9b4f0ff008a
doc_id: 829435
cord_uid: kjqb4yyk

In this survey study of institutions across the US, marked variability in evaluation, treatment, and follow-up of adolescents 12 through 18 years of age with mRNA COVID-19 vaccine-associated myopericarditis (VAM) was noted. Only one adolescent with life-threatening complications was reported with no deaths at any of the participating institutions.

J o u r n a l P r e -p r o o f Since April 2021, more than one thousand patients have been reported to the Vaccine Adverse Event Reporting System (VAERS) with presumed myopericarditis following administration of mRNA COVID-19 (Pfizer-BioNTech, Moderna) vaccine. 1 The afflicted patients predominantly have been males younger than 16 years of age, a vast majority of whom developed clinical features of myopericarditis within a few days after receiving the second mRNA COVID-19 vaccine (Pfizer-BioNTech, BNT162b2) dose. 1 The overall reported incidence of myopericarditis after administration of mRNA COVID-19 vaccine has been estimated to be 4.2 and 32.4 per million doses administered in females and males 12 through 17 years of age, respectively. 2,3

Case series 4 and several other reports suggest wide variability in clinical evaluation and treatment of adolescents 12-18 years of age with mRNA COVID-19 vaccine-associated myopericarditis (VAM) across institutions within the United States (US). [5] [6] [7] [8] [9] [10] In order to better assess this variability, we conducted a cross-sectional survey of pediatric institutions across the US between July 9, 2021 and August 9, 2021. A secondary objective of this study was to determine the rate of serious, life-threatening complications (cardiopulmonary arrest requiring resuscitation, need for mechanical circulatory support [extracorporeal membrane oxygenation, Impella or ventricular assist device use], and death) in these adolescents.

After obtaining appropriate IRB approval, a questionnaire which inquired about the institutional practices regarding diagnosis, treatment and follow-up of adolescents with VAM was emailed to J o u r n a l P r e -p r o o f pediatric cardiologists or pediatric infectious disease specialists at 107 institutions (the top 100 institutions in the US News ranking of pediatric cardiology programs and a few additional programs with which the authors were familiar) across the US between July 9, 2021 and August 9, 2021. 11 The survey was forwarded to content experts for face validity. 12 A follow-up email was sent 2 weeks later if there was no response to the initial email. Nonparametric statistical tests were used to evaluate differences in medians and p-values < 0.05 were considered significant.

The details of the IRB process, the questionnaire, data analysis, and statistics are provided in Appendices 1 and 2 (available at www.jpeds.com).

Fifty-seven institutions (53 %) returned a completed survey. As per the US Census Bureau classification, approximately two-thirds of the participating institutions were located in either the Midwest or the South and a majority had a bed capacity of >200 beds (Appendix 1, Figure 1 Clinical symptoms of concern following administration of mRNA COVID-19 vaccine J o u r n a l P r e -p r o o f All 31 institutions that responded to this question reported chest pain (100%) as a symptom of concern following administration of mRNA COVID-19 vaccine. Other concerning symptoms included shortness of breath (n=27, 87%), chest tightness (n=18, 56%), palpitations (n=26, 81%), and fever (n=16, 50%). The median duration of symptoms which prompted evaluation for VAM was 1 day (range: 0 to 4 days). A majority of institutions reported symptoms after the second dose of mRNA COVID-19 vaccine (Appendix 1).

Cardiac biomarkers (n responding = 54).Most institutions utilized cardiac troponin or CK-MB (98%), use of NT-proBNP was also common (79%) (Appendix 1).

COVID-19 antibody testing (n=54). COVID-19 antibody testing was performed by a majority (98%) of the institutions on these adolescents; however, a positive antibody test was included in diagnostic criteria for VAM by only a few (22%, 7/32) (Appendix 1). Common echocardiographic and CMR findings which were considered potentially consistent with a diagnosis of VAM are shown in Table II (available at www.jpeds.com). Global ventricular dysfunction, pericardial effusion and atrioventricular valve regurgitation were the three most common echocardiographic abnormalities. A combination of late gadolinium enhancement, myocardial edema and pericardial effusion was considered suggestive of VAM by 75% of the institutions.

Pediatric cardiologists were involved in management of these adolescents, most of whom were hospitalized.(Appendix 1).

There was wide variability in the first-line medications utilized to treat adolescents with VAM. A majority (35/54, 66%) of institutions initially treated these adolescents with non-steroidal anti-inflammatory drugs (NSAIDs). The initial treatment consisted of IVIG at a few institutions (n=2, 4%). Other institutions treated with a combination of drugs (Appendix 1). One institution reported only conservative treatment without any specific medication. The criteria utilized to determine response to therapy were highly variable (Appendix 1).

Although corticosteroids and IVIG were indicated as the most common second-and third-line therapeutic agents, there was marked variability (Appendix 1).

Hospitalization (n=49). The median upper limit of duration of hospitalization for the illness was 4 days (range: 1-21 days) while the median of the lower limit of hospitalization for the illness was one day (range: few hours to 5 days) across 49 institutions.

Respiratory support . Only one institution cared for an adolescent VAM who required ventilatory support. Eight institutions indicated using oxygen via nasal cannula and 4 indicated using high flow nasal cannula. institutions between 12 to 24 weeks. Thirty-two (66%) of the institutions recommended a stress test prior to return to full activity (Appendix 1).

The findings of our study, which included 57 institutions across the US, show that there is The treatment of these patients was also widely variable. A pediatric cardiologist was central to management of these patients with additional support from pediatric infectious disease and other specialists at some institutions. Although non-steroid anti-inflammatory drugs (NSAIDs) were the most commonly used first-line agents for treatment of these patients, steroids and IVIG were the most likely to be utilized second-and third-line agents, respectively. However, marked variability was noted in the first-line, second-line and third-line therapeutic regimens with a number of institutions utilizing drug combinations. Most institutions admitted these adolescents for evaluation and management; however, a few managed these adolescents in the outpatient setting with reported good outcomes.

Heart rhythm problems were common in these patients with one-third of the institutions reporting patients with new-onset ectopy, heart block or arrhythmia. The findings of this survey study are consistent with the results of prior studies which have shown a high arrhythmia burden in adolescents hospitalized with acute myocarditis. 15 Approximately 20% of the institutions also reported adolescents with VAM who required respiratory support via nasal cannula. However, serious adverse outcomes were rare with only one institution reporting an adolescent who required ECMO support. The overall reported incidence of myopericarditis after administration of mRNA COVID-19 vaccine has been estimated to be 4. 16 Thus, the findings of this multi-institutional study are consistent with recently published VAERS data and affirm the findings of prior smaller reports and case-series which suggest excellent short-term outcomes in these patients. [4] [5] [6] [7] [8] [9] [10] 16 In addition, because the VAERS is critically dependent on reporting by practitioners and institutions, adverse events can be missed due to a lack of reporting. Our data, gathered from a large number of institutions across the US, provides an independent affirmation of the fact that serious life-threatening adverse events are extremely rare in adolescents with VAM.

Prior reports have shown that electrocardiographic abnormalities are common in adolescents with VAM at the time of initial diagnosis, 4 however, only a handful were noted to have persistent abnormalities on 12-lead electrocardiogram or Holter monitoring suggesting that the electrocardiographic abnormalities noted in the acute phase are very likely to resolve within a J o u r n a l P r e -p r o o f few weeks. A majority of institutions indicated obtaining a cardiac MRI and an echocardiogram at follow-up visits; however, there was marked variability in the timing of these investigations.

As per the current ACC guidelines, athletes diagnosed with myocarditis should be restricted from exercise for 3-6 months to promote resolution of inflammation, especially if extensive inflammation is noted on cardiac MRI. 17 Previous studies have shown extensive myocardial involvement in adolescents with VAM in the absence of significant echocardiographic abnormalities. 4, 8, 9 However, marked variability in return to activity recommendations was noted in our study; almost one-half of the institutions indicated allowing these adolescents to return to full activity by 12 weeks. Only two-thirds of the institutions indicated considering a stress test prior to returning to full activity.

Despite the observed variability in diagnosis and management, the short-term outcomes in adolescents with VAM were good and the majority recovered completely. Although treatment regimens differed, there was no significant difference in the lower (1.69 ± 0.84 vs 2.29 ± 1.3 days; p=14) or the upper (5.41 ± 3.7 vs 4.1± 1.6 days; p=0.27) limit of duration of hospitalization between those adolescents who were treated with only NSAIDs versus those who were treated with multidrug regimens. The variability highlighted by our study is reflective of the challenges faced by clinicians who were using their best judgement in the absence of robust guiding data. In the short-term, our data, which shows that life-threatening complications are extremely rare in adolescents with VAM, is quite encouraging and should motivate the population to receive COVID-19 vaccination.

J o u r n a l P r e -p r o o f 20 Our study had several limitations. Because this was a survey study, data for individual patients was not sought; therefore, the overall accuracy of data may not be comparable with an observational study. However, to enhance the quality of the data, the surveys were directed to physicians who directly participated in the care of adolescents with VAM. Several institutions had no or only a few adolescents with VAM. The responses from these centers might indicate diagnostic and treatment modalities which are likely to be utilized than the ones which were used. A majority of the participating centers were located in either the Midwest or the South. The responses could therefore reflect the prevailing practices in these geographic regions.

Nevertheless, given the large number of centers that participated, our study does provide an estimate of various diagnostic and therapeutic aspects of VAM in adolescents across the US. If the responses of the institutions that responded were fundamentally different from the institutions that did not respond, this could bias the results. The response rate however is comparable with other survey studies which were conducted across a large geographic region. 18 Because it is difficult to survey all providers, it is possible that patients with mild VAM could have been under-reported. Lastly, if the survey was completed by an infectious disease physician, the recognition of cardiology protocols may have been incomplete.

Our study informs the need for consensus guidelines to help facilitate prompt diagnosis and optimal management of these adolescents. In addition, the findings of our study affirm that serious life-threatening complications due to VAM remain rare in adolescents.

J o u r n a l P r e -p r o o f Table and Figure Legends   Table 1 . Laboratory, electrocardiographic, and imaging abnormalities considered suggestive of mRNA COVID-19 vaccine-associated myopericarditis (n=26).

*CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, BNP: Brain-type natriuretic peptide, pro-NT-BNP: pro-N-Terminal-Brain type natriuretic peptide, MRI: Magnetic resonance imaging. Pericardial effusion 22 (76%) * 75% of institutions considered a combination of late gadolinium enhancement, myocardial edema and pericardial effusion to be diagnostic of mRNA COVID-19 vaccine associated myocarditis.

Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Coronavirus disease 2019

Myocarditis With COVID-19 mRNA Vaccines

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination

Epub ahead of print

Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19

Epub ahead of print

Myopericarditis after the Pfizer mRNA COVID-19 Vaccine in Adolescents

Vaccination-Associated Myocarditis in Adolescents

Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine

An Innovative Pilot Curriculum Training Pediatric Residents in Referral and Communication Skills on a Cardiology Rotation

Inhospital arrhythmia development and outcomes in pediatric patients with acute myocarditis

Adolescent Myocarditis After COVID-19 Vaccination Is Rare

Sport Recommendations for Athletes With Cardiomyopathies, Myocarditis, Pericarditis -American College of Cardiology (acc.org)

Management practices for West syndrome in South Asia: A survey study and meta-analysis